公开(公告)号：US20170159024A1

公开(公告)日：2017-06-08

申请号：US15296912

申请日：2016-10-18

Applicant: Public University Corporation Yokohama City University

Inventor： Hideki TANIGUCHI ,  Takanori TAKEBE

IPC: C12N5/071 ,  A61K35/407 ,  A01K67/027 ,  A61K35/39 ,  A61K49/00

CPC classification number: C12N5/0697 ,  A01K67/0271 ,  A01K2207/12 ,  A01K2267/03 ,  A61K35/12 ,  A61K35/28 ,  A61K35/39 ,  A61K35/407 ,  A61K35/44 ,  A61K35/545 ,  A61K49/0008 ,  A61L27/3804 ,  A61L27/3808 ,  A61L27/3834 ,  A61L27/3886 ,  A61L27/54 ,  A61L2300/412 ,  A61L2300/414 ,  A61L2430/26 ,  A61L2430/28 ,  C12N5/0671 ,  C12N5/0677 ,  C12N2501/115 ,  C12N2501/12 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2502/1358 ,  C12N2502/28 ,  C12N2506/45 ,  C12N2533/54 ,  C12N2533/90

Abstract: The present invention provides a means for reconstituting tissues and organs having mature functions.A method of preparing a tissue or an organ, comprising coculturing an organ cell with a vascular endothelial cell and a mesenchymal cell, generating an organ bud, transplanting the organ bud into a non-human animal, and then isolating from the non-human animal the transplanted organ bud-derived tissue or organ.

公开(公告)号：US20170095595A1

公开(公告)日：2017-04-06

申请号：US15380350

申请日：2016-12-15

Applicant: FUJIFILM Corporation

Inventor： Kentaro NAKAMURA

IPC: A61L27/38 ,  A61L27/56 ,  A61L27/22

CPC classification number: A61L27/3878 ,  A61K35/28 ,  A61L27/00 ,  A61L27/222 ,  A61L27/3808 ,  A61L27/3834 ,  A61L27/56 ,  A61L2430/32 ,  C07K14/78

Abstract: An object of the present invention is to provide a cell structure for brain damage treatment which does not contain glutaraldehyde and in which it is possible to exhibit a sufficient effect of treating brain damage, a production method thereof, and a brain damage treatment agent. According to the present invention, there is provided a cell structure for brain damage treatment which contains biocompatible macromolecular blocks and at least one kind of cell and in which a plurality of the biocompatible macromolecular blocks are disposed in gaps between a plurality of the cells, in which the tap density of the biocompatible macromolecular block is 10 mg/cm3 to 500 mg/cm3 or a value obtained by dividing a square root of a cross-sectional area in a two-dimensional cross-sectional image of the biocompatible macromolecular block by a peripheral length is 0.01 to 0.13.

公开(公告)号：US09526815B2

公开(公告)日：2016-12-27

申请号：US14240200

申请日：2012-08-21

Applicant: Victoria L. Boyes ,  Chris Sammon ,  Christine Lemaitre ,  Chris Breen

Inventor： Victoria L. Boyes ,  Chris Sammon ,  Christine Lemaitre ,  Chris Breen

IPC: A61L31/16 ,  A61L31/12 ,  A61L27/52 ,  A61L31/14 ,  C08K3/34 ,  A61L27/24 ,  A61L27/38 ,  A61L27/44

CPC classification number: A61L31/128 ,  A61L27/24 ,  A61L27/3808 ,  A61L27/44 ,  A61L27/52 ,  A61L31/145 ,  A61L31/16 ,  A61L2300/20 ,  C08K3/346 ,  C08L89/06

Abstract: A nanocomposite hydrogel formed from free radical dissociation of an initiator and polymerization of a water soluble monomer. The resulting hydrogel finds particular application within the medical field for both soft and hard tissue repair in human and animals. The hydrogel is particularly advantageous for spinal disc repair.

Abstract translation: 由引发剂的自由基解离和水溶性单体的聚合形成的纳米复合水凝胶。 所得水凝胶在医疗领域中特别适用于人和动物的软组织修复和硬组织修复。 水凝胶对椎间盘修复特别有利。

公开(公告)号：US20160287756A1

公开(公告)日：2016-10-06

申请号：US15146613

申请日：2014-11-04

Applicant: President and Fellows of Harvard College

Inventor： Jennifer A. Lewis ,  David B. Kolesky ,  Mark A. Skylar-Scott ,  Kimberly A. Homan ,  Ryan L. Truby ,  Amelia Sydney Gladman

IPC: A61L27/50 ,  A61L27/22 ,  A61F2/06 ,  B29C67/00 ,  B33Y10/00 ,  B33Y80/00 ,  A61L27/38 ,  A61L27/36

CPC classification number: A61L27/507 ,  A61F2/06 ,  A61F2/105 ,  A61F2240/002 ,  A61L27/222 ,  A61L27/225 ,  A61L27/3633 ,  A61L27/3808 ,  A61L27/3813 ,  A61L27/3826 ,  A61L2430/34 ,  B29C64/106 ,  B29C64/40 ,  B33Y10/00 ,  B33Y80/00 ,  C12M33/00

Abstract: A printed tissue construct comprises one or more tissue patterns, where each tissue pattern comprises a plurality of viable cells of one or more predetermined cell types. A network of vascular channels interpenetrates the one or more tissue patterns. An extracellular matrix composition at least partially surrounds the one or more tissue patterns and the network of vascular channels. A method of printing a tissue construct with embedded vasculature comprises depositing one or more cell-laden filaments, each comprising a plurality of viable cells, on a substrate to form one or more tissue patterns. Each of the one or more tissue patterns comprises one or more predetermined cell types. One or more sacrificial filaments, each comprising a fugitive ink, are deposited on the substrate to form a vascular pattern interpenetrating the one or more tissue patterns. The vascular pattern and the one or more tissue patterns are at least partially surrounded with an extracellular matrix composition. The fugitive ink is then removed to create vascular channels in the extracellular matrix composition, thereby forming an interpenetrating vascular network in a tissue construct.

Abstract translation: 印刷的组织结构包括一个或多个组织图案，其中每个组织图案包括一个或多个预定细胞类型的多个活细胞。 血管通道网络穿过一个或多个组织模式。 细胞外基质组合物至少部分地包围一个或多个组织模式和血管通道的网络。 印刷具有嵌入脉管系统的组织构建体的方法包括在衬底上沉积一个或多个包含多个活细胞的细胞细胞丝，以形成一个或多个组织图案。 一个或多个组织图案中的每一个包括一个或多个预定的细胞类型。 一个或多个牺牲丝，每个包括一种短效油墨，沉积在该基底上以形成一个或多个组织图案互穿的血管图案。 血管图案和一个或多个组织图案至少部分地被细胞外基质组合物包围。 然后除去逸散性油墨以在细胞外基质组合物中产生血管通道，从而在组织构建体中形成互穿血管网络。

公开(公告)号：US20160177270A1

公开(公告)日：2016-06-23

申请号：US14906699

申请日：2014-07-15

Applicant: PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY

Inventor： Takanori TAKEBE ,  Hideki TANIGUCHI ,  Yoshinobu TAKAHASHI

IPC: C12N5/071 ,  A61K49/00 ,  A61K35/28 ,  G01N33/50 ,  A61K35/44

CPC classification number: C12N5/0691 ,  A01K67/0271 ,  A01K2207/12 ,  A01K2267/0325 ,  A01K2267/0331 ,  A01K2267/035 ,  A01K2267/0362 ,  A61K35/28 ,  A61K35/44 ,  A61K49/0008 ,  A61L27/3808 ,  A61L27/3834 ,  A61L27/3886 ,  C07D499/21 ,  C12N2502/13 ,  G01N33/5082

Abstract: The present invention provides a method of constituting a tissue construct in vitro using a tissue without depending on scaffold materials.A method of integrating a biological tissue with a vascular system in vitro, comprising coculturing a biological tissue with vascular cells and mesenchymal cells. A biological tissue which has been integrated with a vascular system by the above-described method. A method of preparing a tissue or an organ, comprising transplanting the biological tissue described above into a non-human animal and differentiating the biological tissue into a tissue or an organ in which vascular networks have been constructed. A method of regeneration or function recovery of a tissue or an organ, comprising transplanting the biological tissue described above into a human or a non-human animal and differentiating the biological tissue into a tissue or an organ in which vascular networks have been constructed. A method of preparing a non-human chimeric animal, comprising transplanting the biological tissue described above into a non-human animal and differentiating the biological tissue into a tissue or organ in which vascular networks have been constructed. A method of evaluating a drug, comprising using at least one member selected from the group consisting of the biological tissue described above, the tissue or organ prepared by the method described above, and the non-human chimeric animal prepared by the method described above. A composition for regenerative medicine, comprising a biological tissue which has been integrated with a vascular system by the method described above.

Abstract translation: 本发明提供了一种使用组织在体外构建组织构建体而不依赖于支架材料的方法。 一种将生物组织与血管系统体外整合的方法，包括将生物组织与血管细胞和间充质细胞共培养。 通过上述方法与血管系统整合的生物体组织。 一种制备组织或器官的方法，包括将上述生物组织移植到非人动物中并将生物组织分化成其中构建血管网络的组织或器官。 一种组织或器官的再生或功能恢复的方法，包括将上述生物组织移植到人或非人动物中并将生物组织分化成其中构建血管网络的组织或器官。 一种制备非人嵌合动物的方法，包括将上述生物组织移植到非人动物中，并将生物组织分化成其中构建血管网络的组织或器官。 一种药物评价方法，其特征在于，使用选自上述生物体组织的组中的至少一种，通过上述方法制备的组织或器官，以及通过上述方法制备的非人嵌合动物。 一种用于再生医学的组合物，包括通过上述方法与血管系统整合的生物组织。

公开(公告)号：US09364565B2

公开(公告)日：2016-06-14

申请号：US11119291

申请日：2005-04-29

Applicant: Michael John Bradley Kutryk ,  Robert J. Cottone, Jr. ,  Stephen M. Rowland

Inventor： Michael John Bradley Kutryk ,  Robert J. Cottone, Jr. ,  Stephen M. Rowland

IPC: A61F2/06 ,  A61F2/82 ,  A61K48/00 ,  C12N15/87 ,  A61K47/48 ,  A61L27/30 ,  A61L27/34 ,  A61L27/38 ,  A61L27/54 ,  A61L29/08 ,  A61L29/10 ,  A61L29/16 ,  A61L31/08 ,  A61L31/10 ,  A61L31/16 ,  C12N5/071 ,  A61K35/12

CPC classification number: A61K47/48992 ,  A61K35/12 ,  A61K47/6957 ,  A61K48/005 ,  A61L27/303 ,  A61L27/34 ,  A61L27/3808 ,  A61L27/54 ,  A61L29/085 ,  A61L29/103 ,  A61L29/16 ,  A61L31/084 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/258 ,  A61L2300/416 ,  A61L2300/64 ,  C12N5/0692 ,  C12N2510/00

Abstract: Therapeutic and drug delivery systems are provided in the form of medical devices with coatings for capturing and immobilizing target cells such as circulating progenitor or genetically-altered mammalian cells in vivo. The genetically-altered cells are transfected with genetic material for expressing a marker gene and at least one therapeutic gene in a constitutively or controlled manner. The marker gene is a cell membrane antigen not found in circulating cells in the blood stream and therapeutic gene encodes a peptide for the treatment of disease, such as, vascular disease and cancer. The coating on the medical device may be a biocompatible matrix comprising at least one type of ligand, such as antibodies, antibody fragments, other peptides and small molecules, which recognize and bind the target cells. The therapeutic and/or drug delivery systems may be provided with a signal source such as activator molecules for stimulating the modified cells to express and secrete the desired marker and therapeutic gene products.

公开(公告)号：US20160074558A1

公开(公告)日：2016-03-17

申请号：US14950567

申请日：2015-11-24

Applicant: ORGANOVO, INC.

Inventor： Keith MURPHY ,  Scott DORFMAN ,  Nathan SMITH ,  Larry BAUWENS ,  Ian SOHN ,  Tim MCDONALD ,  Chris LEIGH-LANCASTER ,  Richard Jin LAW

IPC: A61L27/38 ,  B01L3/02 ,  C12M3/00

CPC classification number: A61L27/3808 ,  A61L27/3826 ,  B01L3/0268 ,  B28B1/001 ,  B29C64/106 ,  B29C64/112 ,  B29C64/118 ,  B29C64/20 ,  B33Y30/00 ,  B33Y50/02 ,  B33Y70/00 ,  B41J3/407 ,  C12M21/08 ,  C12M33/00

Abstract: Described herein are bioprinters comprising: one or more printer heads, wherein a printer head comprises a means for receiving and holding at least one cartridge, and wherein said cartridge comprises contents selected from one or more of: bio-ink and support material; a means for calibrating the position of at least one cartridge; and a means for dispensing the contents of at least one cartridge. Further described herein are methods for fabricating a tissue construct, comprising: a computer module receiving input of a visual representation of a desired tissue construct; a computer module generating a series of commands, wherein the commands are based on the visual representation and are readable by a bioprinter; a computer module providing the series of commands to a bioprinter; and the bioprinter depositing bio-ink and support material according to the commands to form a construct with a defined geometry.

公开(公告)号：US20160030637A1

公开(公告)日：2016-02-04

申请号：US14777397

申请日：2014-03-13

Applicant: MIROMATRIX MEDICAL INC.

Inventor： Jeffrey Ross ,  Dominique Seetapun

IPC: A61L27/38 ,  A61L27/36 ,  C12N5/071

CPC classification number: A61L27/3808 ,  A61L27/3633 ,  A61L27/3683 ,  A61L27/3804 ,  A61L27/3834 ,  A61L27/48 ,  A61L27/507 ,  C12N5/069

Abstract: The invention provides a method for maintaining capillary lumen diameter, reducing a decrease in capillary vessel lumen diameter or expanding capillary vessel lumen diameter in a re-endothelialized decellularized organ or tissue graft with an intact extracellular matrix vascular network. The method is based on administration of endothelial cells and microparticles to the decellularized ECM.

Abstract translation: 本发明提供了一种用于维持毛细血管内径直径，减少毛细血管腔直径的减少或在具有完整的细胞外基质血管网络的再内皮化脱细胞器官或组织移植物中扩张毛细血管管腔直径的方法。 该方法基于将内皮细胞和微粒施用于脱细胞化ECM。

公开(公告)号：US20150374881A1

公开(公告)日：2015-12-31

申请号：US14758058

申请日：2013-12-27

Applicant: NITTA GELATIN INC. ,  CORNEA REGENERATION INSTITUTE CO., LTD.

Inventor： Satoru YAMAGAMI ,  Nobuyuki SHIMA ,  Miwa YAMAUCHI ,  Masahiro YAMAGUCHI ,  Yosuke HIRAOKA

IPC: A61L27/38 ,  A61L27/34 ,  A61L27/54 ,  A61L27/36 ,  A61L27/22

CPC classification number: A61L27/3808 ,  A61L27/22 ,  A61L27/222 ,  A61L27/24 ,  A61L27/34 ,  A61L27/3641 ,  A61L27/3691 ,  A61L27/54 ,  A61L2300/64 ,  A61L2430/16 ,  C12N5/0621 ,  C12N2533/52 ,  C12N2533/54 ,  C12N2535/00 ,  C12N2537/10 ,  C08L89/06

Abstract: The present invention provides a human corneal endothelial cell sheet having a curvature fitting a human corneal endothelial surface, particularly, the human corneal endothelial cell sheet supported by a cell support having a curvature fitting a human corneal endothelial surface, and a production method of a human corneal endothelial cell sheet having a curvature fitting a human corneal endothelial surface, which includes the following steps: (1) a step of gelling a gelatin aqueous solution poured into a template having a curvature fitting a human corneal endothelial surface; (2) a step of forming a sheet-like gelatin by drying the gelled gelatin obtained in (1); (3) a step of obtaining a gelatin sheet by thermally crosslinking the sheet-like gelatin obtained in (2); (4) a step of seeding human corneal endothelial cells on the gelatin sheet obtained in (3) to form a human corneal endothelial cell layer.

Abstract translation: 本发明提供一种人角膜内皮细胞片，其具有拟合人角膜内皮表面的曲率，特别是由具有适合人角膜内皮表面的曲率的细胞支撑体支撑的人角膜内皮细胞片，以及人的角膜内皮细胞片的生产方法 具有适合人角膜内皮表面的曲率的角膜内皮细胞片，其包括以下步骤：（1）将明胶水溶液胶凝的步骤，将其倾入具有适合人角膜内皮表面的曲率的模板中; （2）通过干燥（1）得到的凝胶状明胶来形成片状明胶的工序; （3）通过将（2）中得到的片状明胶热交联而得到明胶片的工序; （4）将人角膜内皮细胞接种于（3）得到的明胶片上，形成人角膜内皮细胞层的步骤。

公开(公告)号：US20150297794A1

公开(公告)日：2015-10-22

申请号：US14385086

申请日：2013-03-15

Applicant: IHEART JAPAN CORPORATION

Inventor： Jun YAMASHITA ,  Hidetoshi MASUMOTO

IPC: A61L27/38 ,  A61L27/50 ,  A61L27/54 ,  C12N5/071

CPC classification number: A61L27/3886 ,  A61K35/34 ,  A61K35/44 ,  A61K35/545 ,  A61L27/3804 ,  A61L27/3808 ,  A61L27/3826 ,  A61L27/3834 ,  A61L27/3839 ,  A61L27/3895 ,  A61L27/50 ,  A61L27/54 ,  A61L2300/608 ,  A61L2300/64 ,  A61L2430/20 ,  C12N5/0602 ,  C12N5/0657 ,  C12N5/069 ,  C12N5/0697 ,  C12N2500/44 ,  C12N2501/115 ,  C12N2501/16 ,  C12N2501/165 ,  C12N2501/727 ,  C12N2502/1329 ,  C12N2502/28 ,  C12N2506/45 ,  C12N2539/10 ,  A61K2300/00

Abstract: The present invention provides: a method for producing mixed cells comprising cardiomyocytes, endothelial cells and mural cells from induced pluripotent stem cells, the method comprising (a) a step of producing cardiomyocytes from induced pluripotent stem cells and (b) a step of culturing the cardiomyocytes in the presence of VEGF; and a therapeutic agent for heart diseases, comprising the mixed cells produced by the method.

Abstract translation: 本发明提供：一种从诱导的多能干细胞产生包含心肌细胞，内皮细胞和壁细胞的混合细胞的方法，所述方法包括（a）从诱导的多能干细胞产生心肌细胞的步骤，和（b） 在VEGF存在下的心肌细胞; 和用于心脏病的治疗剂，其包含通过该方法制备的混合细胞。